Serum Levels of Cytokines and Soluble Cytokine Receptors in Patients with Metastatic Renal Cell Carcinoma or Malignant Melanoma Receiving IL-2/Interferon-α Combination Therapy

References

• Fosså S D, Stenwig A E, Lien H H. Long-term results in patients with metastatic renal cell carcinoma treated with Inter-feron with or without vinblastine. World J Urol 1991; 9: 210–4
   Google Scholar
• Dillman R O, Church C, Oldham R K, West W H, Schwartzberg L, Birch R. Impatient continuous-infusion Interleukin-2 in 788 patients with cancer. Cancer 1993; 71: 2358–70
   PubMedGoogle Scholar
• Funke I, Späht-Schwalbe E, Stohlmann G, et al. Subcutaneous IL-2 and low dose IFN-α2A in the treatment of unse-lected patients with advanced renal cell cancer. Onkologie 1994, in press
   Google Scholar
• Palmer P A, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3: 475–80
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T, Yang J C, et al. Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1873–4
   Google Scholar
• Fujiwara T, Grimm E A. Specific inhibition of interleukin 1β gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells. Cancer Res 1992; 52: 4954–9
   PubMed Web of Science ®Google Scholar
• Naume B, Shalaby R, Lesslauer W, Espevik T. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunology 1991; 146: 3054–8
   Google Scholar
• Philip R, Epstein L B. Tumour necrosis factor as immuno-modulator and mediator of monocyte cytotoxicity induced by itself, τ-interferon and interleukin-1. Nature 1986; 323: 86–9
   PubMed Web of Science ®Google Scholar
• Ranges G E, Figari I S, Espevik T, Isaacs H, Jr. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 1987; 166: 991–8
   PubMed Web of Science ®Google Scholar
• Smith K A. T-cell growth factor. Immunological Rev 1980; 51: 337–57
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Matsumoto-Kobayashi M, Clark S C, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interlleukin-2. J Exp Med 1984; 160: 1147–69
   PubMed Web of Science ®Google Scholar
• Horoszewicz J S, Murphy G P. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989; 142: 1173–80
   PubMed Web of Science ®Google Scholar
• Iigo M, Salurai J, Tamura T, Saijo N, Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin-2 alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988; 48: 260–4
   PubMed Web of Science ®Google Scholar
• Weber J S, Jay G, Tanaka K, Rosenberg S A. Immunotherapy of a murine tumor with interleukin-2: Increased sensitivity after MHC class I gene transfection. J Exp Med 1987; 166: 1716–33
   PubMed Web of Science ®Google Scholar
• Sidky Y A, Borden E C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5255–61
   Google Scholar
• Loetscher H, Pan Y-C E, Lahm H-W, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1986; 61: 351–9
   Google Scholar
• Smith C A, Davis T, Amderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019–23
   PubMed Web of Science ®Google Scholar
• Gatanaga T, Hwang C, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781–4
   PubMed Web of Science ®Google Scholar
• Waage A, Liabakk N, Lien E, Lamvik J, Espevik T. p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 1992; 10: 2577–83
   Google Scholar
• Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp Med 1992; 175: 323–9
   PubMed Web of Science ®Google Scholar
• Fosså S D, Aune H, Baggerud E, Granerud T, Heilo A, Theodorsen L. Continuous intravenous Interleukin-2 infusion and subcutaneous Interferon-α in metastatic renal cell carcinoma: worth to use in today's oncological routine practice? Eur J Cancer Oncol 1993; 9: 1313–5
   Google Scholar
• Barrera P, Boerbooms A MTh, Janssen E M, et al. Circulating soluble TNF receptors and Interleukin-2 receptors, tunor necrosis factor alpha and Interleukin-6 in rheumatoid arthritis. Longitudinal evaluation during methotrex-ate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Pierce W, Sayah D, et al. Soluable tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with Interleukin-2 based im-munotherapy. J Immunother 1993; 13: 175–80
   Web of Science ®Google Scholar
• Lotze M T, Custer M C, Sharrow S O, Rubin L A, Nelson D L, Rosenberg S A. In vivo administration of purified human Interleukin-2 to patients with cancer: Development of Interleukin-2 receptor positive cells and circulating soluble Interleukin-2 receptors following Interleukin-2 administration. Cancer Res 1987; 47: 2188–95
   PubMed Web of Science ®Google Scholar
• Spiers E M, Potts R C, Sharpe S Y, et al. Response of soluble IL-2 receptor levels to repeated cycles of IL-2 immunother-apy/chemotherapy. Eur J Cancer 1993; 29A: 298
   PubMedGoogle Scholar
• Watson J M, Sensintaffar J L, Berek J, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian tumor cultures. Cancer Res 1990; 50: 6959–65
   PubMed Web of Science ®Google Scholar
• Moradi M M, Carson L F, Weinberg J B, Haney A F, Twiggs L B, Ramakrishnan S. Serum and ascitic fluid levels of Interleukin-1, Interleukin-6 and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993; 72: 2433–40
   PubMed Web of Science ®Google Scholar